Actinium Pharmaceuticals, Inc.
ATNM evidence brief
What we can confirm
- BioSniper Score:
- 8.4 / 10
- Market Cap:
- $37.1M
- Lead Asset:
- Actimab-A (Phase 2/Phase 3)
What it means
What to watch
Prepared research question
What matters most for ATNM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ATNM
Actinium Pharmaceuticals, Inc. (ATNM) is a clinical-stage biopharmaceutical company developing targeted radiotherapies for oncology, with a focus on solid tumors and hematologic malignancies [sec_mda · as of 2026-08-07].
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$37.1M
Cash Runway
—
Lead Asset
Actimab-A (Phase 2/Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 3 clinical trials for Actinium Pharmaceuticals, Inc..
Actinium Pharmaceuticals, Inc. (ATNM) is a clinical-stage biopharmaceutical company developing targeted radiotherapies for oncology, with a focus on solid tumors and hematologic malignancies [sec_mda · as of 2026-08-07].
- Cash & equivalents of $36.5M as of 2026-06-30 [sec].
- Total revenue of $35.0M and net income of $27.9M as of 2026-06-30 [sec].
- Shareholders' equity of $30.3M as of 2026-06-30 [sec].
- Lead solid tumor program ATNM-400 is a first-in-class antibody radioconjugate armed with Actinium-225, with preclinical data in NSCLC and breast cancer [news · published 2025-10-27] [news · published 2025-11-04].
- Iomab-B (apamistamab with I-131) is a CD45-targeting conditioning agent for bone marrow transplant, in Phase 2/3 for R/R AML [pipeline].
What works
- Proprietary cyclotron-based technology for commercial-scale production of Ac-225 addresses a critical bottleneck in radiopharmaceutical development [sec_mda · as of 2026-08-07].
- Iomab-B benefits from composition of matter patents extending to 2038 and a network of 24 clinical sites from the SIERRA trial [sec_mda · as of 2026-08-07].
- Multiple clinical milestones expected in 4Q:2026 and over 2027 across ATNM-400, Actimab-A, and Iomab-ACT programs [sec_mda · as of 2026-08-07].
What to weigh
- The company is clinical-stage and has no approved products, relying on future sales of common stock and equivalents to fund operations [sec_mda · as of 2026-03-30].
- Cash runway is stated as more than 12 months from 2026-03-30, but actual capital requirements depend on many uncertain factors [sec_mda · as of 2026-03-30].
- The company is actively seeking a strategic partner for Iomab-B and may out-license or divest several hematology programs, indicating potential challenges in advancing them independently [sec_mda · as of 2025-11-14].
From the filings
Quoted directly from source documents.
Company description as clinical-stage biopharmaceutical company pioneering targeted radiotherapies
“We are a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology.”
SEC MD&A · August 7, 2026
Iomab-B is a CD45-targeting conditioning agent in Phase 2/3
“Pipeline Candidate: Iomab-B Generic Name: apamistamab with I-131 (myeloablative doses) Indication: Bone marrow transplant conditioning Phase: Phase 2/Phase 3 Mechanism of Action: CD45-targeting conditioning agent”
Proprietary cyclotron-based technology for Ac-225 production
“We have developed proprietary cyclotron-based technology for commercial-scale production of Ac-225, one of the most critical bottlenecks in radiopharmaceutical development.”
SEC MD&A · August 7, 2026
Catalyst timeline
- 2026-04-21 · Phase1_Start: A Phase I Study of Lintuzumab-Ac-225 in Combination With Venetoclax and ASTX-727 in Adults With Newly Diagnosed AML — Initiation of a Phase 1 trial combining lintuzumab-Ac-225 with venetoclax and ASTX-727 in newly diagnosed AML.
- 2026-04-27 · Phase1_Start: Lintuzumab-Ac225 Monotherapy for Patients With Hypomethylating Agent-Refractory Myelodysplastic Syndrome — Start of a Phase 1 monotherapy trial for lintuzumab-Ac225 in MDS patients refractory to hypomethylating agents.
- 2026-06-28 · Phase1_Start: A Phase I Trial of 225Ac-anti-CD33 and PD1-Inhibitor in Recurrent Glioblastoma — Initiation of a Phase 1 trial combining 225Ac-anti-CD33 with a PD1 inhibitor in recurrent glioblastoma.
Risks & what to watch (3)›
Key risks
- No approved products — Company is clinical-stage with no approved products; relies on stock sales for funding [sec_mda · as of 2026-03-30].
- Cash runway uncertainty — Cash runway >12 months from 2026-03-30 but depends on many uncertain factors [sec_mda · as of 2026-03-30].
- Partner dependency for Iomab-B — Actively seeking strategic partner for Iomab-B; may out-license or divest programs [sec_mda · as of 2025-11-14].
What to watch
- Data readouts from ATNM-400, Actimab-A, and Iomab-ACT expected in 4Q:2026 and over 2027 [sec_mda · as of 2026-08-07].
- Progress of Iomab-B Phase 2/3 trial in R/R AML and potential regulatory submissions [sec_mda · as of 2026-08-07].
- Partnering or out-licensing decisions for Iomab-B and other hematology programs [sec_mda · as of 2025-11-14].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Actinium Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Actinium Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.33 · 0% dilution
Lead: Phase 2/Phase 3
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
54
Total value held
$4.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,255,516 | $1.2M |
| millennium management llc | 564,600 | $562K |
| renaissance technologies llc | 471,600 | $469K |
| blackrock, inc. | 371,210 | $369K |
| two sigma investments, lp | 337,168 | $336K |
| geode capital management, llc | 336,073 | $335K |
| gagnon securities llc | 201,300 | $200K |
| vanguard fiduciary trust co | 160,265 | $159K |
| state street corp | 126,215 | $126K |
| susquehanna international group, llp | 123,998 | $123K |
Showing top 10 of 54 institutional holders of Actinium Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 3.4%
- Days to cover
- 3.9
- Shares short
- 1,059,722
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ATNM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Actinium Pharmaceuticals, Inc.?
Actinium Pharmaceuticals, Inc. (ATNM) is a clinical-stage biopharmaceutical company developing targeted radiotherapies for oncology, with a focus on solid tumors and hematologic malignancies [sec_mda · as of 2026-08-07].
What is Actinium Pharmaceuticals, Inc.'s lead drug candidate?
Actinium Pharmaceuticals, Inc.'s most advanced tracked candidate is Actimab-A (Phase 2/Phase 3) for Acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and solid tumors (HNSCC, NSCLC, GBM, MSI-high colorectal cancer).
Who is the CEO of Actinium Pharmaceuticals, Inc.?
Mr. Sandesh C. Seth M.B.A., M.S. is the chief executive officer of Actinium Pharmaceuticals, Inc. (ATNM).
Where is Actinium Pharmaceuticals, Inc. headquartered?
Actinium Pharmaceuticals, Inc. (ATNM) is headquartered in New York, NY, United States.
What therapeutic areas does Actinium Pharmaceuticals, Inc. focus on?
Actinium Pharmaceuticals, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.